Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

HCW Biologics Inc. (HCWB)

2.0373   0.037 (1.87%) 02-03 13:41
Open: 2.03 Pre. Close: 2
High: 2.04 Low: 2.02
Volume: 5,308 Market Cap: 73(M)

Technical analysis

as of: 2023-02-03 2:47:34 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.59     One year: 3.02
Support: Support1: 1.96    Support2: 1.79
Resistance: Resistance1: 2.22    Resistance2: 2.59
Pivot: 2.05
Moving Average: MA(5): 1.98     MA(20): 2.05
MA(100): 2.15     MA(250): 2.26
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 21.1     %D(3): 12.3
RSI: RSI(14): 49.6
52-week: High: 3.31  Low: 1.75
Average Vol(K): 3-Month: 20 (K)  10-Days: 13 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ HCWB ] has closed above bottom band by 42.4%. Bollinger Bands are 9.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.02 - 2.03 2.03 - 2.04
Low: 1.98 - 1.99 1.99 - 2
Close: 1.98 - 2 2 - 2.02

Company Description

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Headline News

Mon, 02 Jan 2023
Organigram And Rounding Out My Tax Loss Selling Basket ... - Seeking Alpha

Thu, 08 Dec 2022
HCW Biologics Enters CRADA with National Cancer Institute - GlobeNewswire

Mon, 07 Nov 2022
Florida's Life Science Leaders United to Celebrate 25 Years of ... - PR Newswire

Mon, 07 Nov 2022
HCW Biologics Reports Third Quarter 2022 Financial Results And ... - GlobeNewswire

Fri, 12 Aug 2022
HCW Biologics Reports Second Quarter 2022 Financial Results And ... - GlobeNewswire

Wed, 03 Aug 2022
U.S. Patent Issued to HCW Biologics for Foundational Platform ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 36 (M)
Shares Float 12 (M)
% Held by Insiders 59.7 (%)
% Held by Institutions 1.8 (%)
Shares Short 24 (K)
Shares Short P.Month 15 (K)

Stock Financials

EPS -0.44
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.19
Profit Margin (%) -235.3
Operating Margin (%) -232.8
Return on Assets (ttm) -14.6
Return on Equity (ttm) -26.3
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0.14
EBITDA (p.s.) -0.34
Qtrly Earnings Growth 0
Operating Cash Flow -10 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -4.66
PEG Ratio 0
Price to Book value 1.71
Price to Sales 13.58
Price to Cash Flow -7.33

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.